First Tracks Biotherapeutics (TRAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, First Tracks Biotherapeutics (TRAX) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.56 Million) by net assets ($257.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View First Tracks Biotherapeutics (TRAX) share price today for real-time trading data and today's change.
First Tracks Biotherapeutics - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how First Tracks Biotherapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see TRAX market cap overview for the company's overall valuation and market capitalisation.
First Tracks Biotherapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of First Tracks Biotherapeutics ranked by their cash flow conversion efficiency. Also see First Tracks Biotherapeutics asset portfolio for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Changfa Refrigeration Co Ltd
SHE:002413
|
0.000x |
|
Dalian Dalicap Technology Co Ltd
SHE:301566
|
N/A |
|
Globant SA
F:2G2
|
0.079x |
|
Bank Ina Perdana PT
JK:BINA
|
-0.047x |
|
Sobha Limited
NSE:SOBHA
|
0.062x |
|
China Yuchai International Limited
NYSE:CYD
|
N/A |
|
Chongqing Zaisheng Tech Corp
SHG:603601
|
0.066x |
|
Métropole Télévision S.A.
PA:MMT
|
0.027x |
Annual Cash Flow Conversion Efficiency for First Tracks Biotherapeutics (2023–2025)
The table below shows the annual cash flow conversion efficiency of First Tracks Biotherapeutics from 2023 to 2025. Review TRAX free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $287.49 Million | $-142.93 Million | -0.497x | -54.75% |
| 2024-12-31 | $391.60 Million | $-125.81 Million | -0.321x | -41.57% |
| 2023-12-31 | $409.85 Million | $-93.00 Million | -0.227x | -- |
About First Tracks Biotherapeutics
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in bo… Read more